Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Apr 6;43(8):4075–4086. doi: 10.1093/nar/gkv273

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — The effect of MAD2L2 siRNA and miR-890, alone or in combination, on IR therapy. (A) MAD2L2 knock-down by siRNA (siMAD2L2), miR-890, or combined siRNA and miR-890 in LNCaP and DU145 cells (10 nM). Western blot 48 h after transfection. ACTB was utilized as a loading reference. (B) IR sensitization potency of siMAD2L2 and/or miR-890 (0.08–10 nM) in LNCaP-MLuc cells. Relative cell viability (mean ± SE, n = 12) is presented as the MLuc activity after IR (4 Gy), as normalized by control miRNA. *, P < 0.05. (C) The calculated IC₅₀ value of each treatment group, based on relative cell viability after IR in LNCaP-MLuc cells. (D) Clonogenic survival assay of DU145 cells transfected with control miRNA, siMAD2L2, miR-890, or combined siRNA and miR-890 (10 nM). The surviving fraction is reported (mean ± SD, n = 3) following the indicated doses of IR. *, P < 0.05 compared with control; **, P < 0.05 compared with siMAD2L2; ***, P < 0.05 compared with miR-890. DMF_0.1 of siMAD2L2, miR-890 and combined siRNA and miR-890 is 1.58, 1.49 and 1.90, respectively.